[Skip to Content]
[Skip to Content Landing]
Views 1,053
Citations 0
From The JAMA Network
January 2, 2018

Expanding the Options for Patient-Guided Decision Making in Papillary Thyroid Cancer

Author Affiliations
  • 1Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA. 2018;319(1):76-77. doi:10.1001/jama.2017.18608

Papillary thyroid cancer (PTC) accounts for 95% of differentiated thyroid cancers and is increasing in incidence at an estimated rate of 4% to 5% per year, with 56 870 cases predicted to be diagnosed in 2017 in the United States.1,2 The majority of patients with PTC have characteristic cytological findings and can be diagnosed by preoperative fine needle aspiration biopsy. Historically, treatment has included thyroidectomy with or without radioactive iodine ablation and is associated with an overall 20-year survival rate of greater than 90%.3 Greater understanding of the biology and natural history of these tumors suggests that not all patients with PTC require the same treatment intensity.